Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**Clinical Insights**

**SARS-CoV-2 vaccine-induced cerebral venous thrombosis**

Alfonso Ciccone*

*Department of Neurology with neurosurgical activity and stroke unit, ASST di Mantova, Mantova, Italy

**ARTICLE INFO**

Keywords:
- Cerebral venous thrombosis
- Cerebral sinus thrombosis
- SARS-CoV-2 vaccination
- AstraZeneca vaccine
- Vaccine-induced immune thrombotic thrombocytopenia
- Immune thrombocytopenia
- Adverse event

**VISUAL ABSTRACT**

The nosological entity of the cerebral venous thrombosis caused by the SARS-CoV-2 vaccination differs from the common cerebral venous thrombosis in that it is due to immune thrombocytopenia triggered by vaccination. Cerebral venous thrombosis is one of several manifestations of this type of immune thrombocytopenia. Albeit many general aspects of management of cerebral venous thrombosis are similar, immune thrombocytopenia requires a specific therapeutic approach, which is not normally adopted for cerebral venous thrombosis due to other causes, therefore its early recognition is essential.

What is a cerebral venous thrombosis?

Cerebral venous thrombosis (CVT) is a rare cause of stroke and intracranial hypertension syndrome. Compared to arterial stroke, CVT affects younger people, predominantly women, has a different risk factors profile, and a subtle and multiform clinical presentation. Risk factors include pregnancy and puerperium, oral contraceptives, inherited thrombophilia, malignancy, infections, obesity, diagnostic and treatment procedures. The wide spectrum of clinical presentations make the diagnosis difficult. The three main connected syndromes are isolated intracranial hypertension syndrome (headache with or without vomiting and papilloedema), focal syndrome (focal deficit such as paresis and aphasia, seizures or both), and encephalopathy (drowsiness, delirium, and consciousness disturbances up to coma) [1].

Non-invasive imaging studies, such as MR imaging with MR venography or CT with CT venography, should be used to confirm the diagnosis; MR with T2*- weighted gradient recalled echo or susceptibility-weighted imaging, allow for the detection of intravenous thrombosis; non-contrast CT, instead, can be normal or have non-specific findings in most patients [2]. Therefore, clinical diagnostic suspicion must guide the correct neuroimaging investigations.

The main therapies for the acute phase are the anticoagulant treatment with either unfractionated intravenous heparin or subcutaneous low molecular weight heparin followed by oral anticoagulation [2] (vitamin K antagonists or dabigatran [3]), even when in presence of brain hemorrhage, and measures to reduce intracranial pressure [1,2].

Early recognition and improvement in CVT treatment has contributed to improve outcome and mortality, which declined below 5% in the last decades [4].

Why a cerebral venous thrombosis after the SARS-CoV-2 vaccine?

The clinicians like myself, who had the chance of coming across a case of CVT following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, realized in the field that this condition is completely different from what we had experienced before. The first clinical aspect that stroked me at the initial observation in the emergency room was the result of the blood tests: the drop of platelet count and the high D-dimers level. While hematological diseases are known risk factor for CVT, these generally include conditions such as essential thrombocythemia, myeloproliferative malignancies, primary and secondary polycythemia, paroxysmal nocturnal hemoglobinuria [5], but not typically thrombocytopenia, which is more frequently linked to hemorrhagic than thrombotic complications. However, cases of CVT have been reported in the course of thrombocytopenia in systemic lupus [6] and of immune thrombocytopenia [7]. The coexistence of thrombosis with thrombocytopenia seems paradoxical [7], unless we explain the phenomenon by a mechanism of systemic platelet consumption and sequestration through agglutination triggered by the vaccine, which ultimately leads to systemic thrombosis. In fact, the reported cases had a median platelet count at diagnosis of 20,000–30,000 per cubic millimeter and almost invariably a high title of antibodies to platelet factor 4.

* Corresponding author Alfonso Ciccone, Department of Neurosciences, ASST di Mantova, Strada Lago Paolo 10, 46100 Mantova, Italy.
E-mail address: alfonso.ciccone@asst-mantova.it.

https://doi.org/10.1016/j.ejim.2021.05.026

Received 27 April 2021; Received in revised form 11 May 2021; Accepted 16 May 2021
Available online 25 May 2021
0953-6205/© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
The occurrence of VITT is rare and is estimated on about 1 subject every 150,000 vaccinated, not far away from the CVT incidence in the general population. This explains why these complications were not seen in SARS-CoV-2 vaccine trials, which involved less than 30,000 subjects per arm.

Although most of the reported cases of VITT, for unknown reasons, are CVT, the possibility of arterial thrombosis in the brain or in other organs should not be excluded. Therefore, we should pay close attention to the frequent thrombo-embolic pathologies, such as stroke of arterial origin, where VITT can be masked by common risk factors for cerebro-vascular pathologies. Indeed, the presence of other risk factors such as atrial fibrillation, diabetes and atherosclerosis could prevent from searching on a much rarer, largely still unknown cause of thrombosis, such as VITT. The early recognition of VITT is fundamental for the consequent therapeutic choices, since these differ from the common CVT. Indeed, the early choice of a correct therapy should prevent the potentially catastrophic evolution of VITT. Early anticoagulant treatment in CVT is widely acknowledged and low-molecular-weight heparin is recommended in guidelines from the European Stroke Organization, although based on limited trial evidence[2]. On the contrary, in CVT linked to VITT low-molecular-weight heparin could possibly worsen the outcome. Likewise, platelet transfusion might be the wrong option because it could amplify the rate of immune thrombosis. Different scientific society published guidelines for the management of VITT, largely borrowed from the experience with heparin-induced thrombocytopenia[18-20]. Although there are some differences, these guidelines have in common the indication to avoid heparin in all its forms, including low-molecular-weight heparin, and avoid platelet transfusion. These therapies have instead been administered to most of the patients reported, including mine, when we were still unaware of VITT. High dosage intravenous immunoglobulins and possibly plasmapheresis are probably effective.

Conclusions

CVT after SARS-CoV-2 vaccination can be the first manifestation of a much more complex and life-threatening disorder, mimicking heparin-induced thrombocytopenia. CVT is not the only manifestation of vaccine-induced immune thrombotic thrombocytopenia, which can also occur with thrombosis in other sites. It is necessary to pay close attention to the most common thrombotic manifestations, such as stroke and myocardial infarction, among subjects with risk factors, because it cannot be excluded that some of these cases are adverse effects of the vaccine.

A headache, which is also a frequent symptom after vaccination, could be a manifestation of a CVT in a vaccine-induced immune thrombotic thrombocytopenia and a simple platelet count could help rule out this form. Conversely, a thrombocytopenia in patients with thrombotic manifestations of any kind within 4 weeks of vaccination (all cases reported so far have occurred within 24 days of vaccination[8-10]), should lead to a search for anti-FP4 antibodies.

A well-rounded awareness of these events’ clinical and laboratory features plays a crucial role in the early identification of patients at their first clinical manifestation and helps undertake all preventions to avoid the dramatic consequences of immune thrombocytopenia. Although the indications on the treatment of vaccine-induced immune thrombotic thrombocytopenia are derived from studies on thrombocytopenia induced by heparin, the widespread knowledge of this possible severe adverse event of SARS-CoV-2 vaccination is already a good starting point.

Declarations of interest

None.

References

[1] Ferro JM, Aguiar de Sousa D. Cerebral Venous Thrombosis: an Update. Curr Neurol Neurosci Rep 2019;19. 74,019-0988-x.
[2] Ferro JM, Bounser MG, Canhao P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017;24:1203-13.
[3] Ferro JM, Coutinho JM, Dentali F, et al. Safety and Efficacy of Dabigatran Etxelate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: a Randomized Clinical Trial. JAMA Neurol 2019;76:1457-65.
[4] Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke 2014;45:1388-41.
[5] Ferro JM, Canhao P, Stam J, Bounser MG, Barinagarrementeria F, Investigators ISCVT. Prognosis of cerebral vein and dural sinus thrombosis: results
Darmawan G, Hamijoyo L, Oehadian A, Bandiara R, Amalia L. Cerebral Venous Sinus Thrombosis in a Patient with Immune Thrombocytopenia, an Apparent Paradox. Case Rep Oncol 2020;13:588–94.

Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrie PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021.

Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021.

Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017;15:2099–114.

Cavalanti DD, Raz E, Shapiro M, et al. Cerebral Venous Thrombosis Associated with COVID-19. AJNR Am J Neuroradiol 2020;41:1370–6.

Bhattacherjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med 2020;1–11.

Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med 2021.

Dentali F, Squizzato A, Marchesi C, Bonzini M, Ferro JM, Ageno W. D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012;10:582–9.

Coutinho JM, Ferro JM, Canhao P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009;40:2356–61.

Gresele P, Marietta M, Ageno W, et al. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (ISISET). Blood Transfus 2021.

British Society for Haematology. Guidance produced from the Expert Haematology Panel (EHP) focused on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination. Available at: https://b-s-h.org.uk/about-us/news/guidance-produced-by-the-expert-haematology-panel-ehp-focused-on-vaccine-induced-thrombosis-and-thrombocytopenia-vipt/. Accessed on 11/05/2021.

Pai M., Schull M., Razak F., et al.; on behalf of the Drugs & Biologics Clinical Practice Guidelines Working Group and the Ontario COVID-19 Science Advisory Table. Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in Emergency Department and Inpatient Settings. Available at: http://covid19-science-table.ca/sciencebrief/vaccine-induced-prothrombotic-immune-thrombocytopenia-vipt-following-astrazeneca-covid-19-vaccination-interim-guidance-for-healthcare-professionals-in-emergency-department-and-inpatient-settings/. Accessed on 11/05/2021.